Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Invex Therapeutics Ltd. ( (AU:IXC) ) just unveiled an announcement.
Invex Therapeutics Ltd has expanded its research collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s Disease, with results expected later in 2025. The company renewed orphan drug designations in Europe and the US for Exenatide, attended the Bio 2025 conference to explore partnerships, and is de-registering its UK subsidiary to reduce overheads. Financially, Invex managed its cash reserves with a closing balance of $5.4 million, focusing on R&D activities with a slight decrease in operating cash outflows.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company that focuses on developing and commercializing Exenatide for neurological conditions related to raised intracranial pressure (ICP). The company is actively involved in research and development, particularly in collaboration with other firms, to explore the potential of Exenatide in treating conditions such as Alzheimer’s Disease and idiopathic intracranial hypertension.
Average Trading Volume: 51,964
Technical Sentiment Signal: Buy
Current Market Cap: A$6.76M
See more data about IXC stock on TipRanks’ Stock Analysis page.